AssureRx Raises $11M in Series B Round

The firm's GeneSightRx technology uses DNA from a cheek swab to measure and analyze genetic variants to determine how a patient will respond to psychotropic medications.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories